^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    05/24/2022
    Excerpt:
    REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with...Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product...
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    01/06/2020
    Excerpt:
    Table 6: Summary of recommendations: EMZL- Other treatments including ChT, immunotherapy or combination chemoimmunotherapy are indicated in patients with symptomatic disseminated disease, contraindications to RT, failure after antibiotics or after local therapy or clinical suspicion of histological transformation: R-chlorambucil [I, A], R-bendamustine [III, A], rituximab monotherapy [III, B], R-lenalidomide [III, C] and R-CHOP for (clinically suspected or biopsy-proven) histological transformation.
    DOI:
    10.1016/j.annonc.2019.10.010
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphoma: First-line therapy…Other recommended regimens…Lenalidomide + rituximab (category 2B)
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    HEMO 2020
    Title:

    INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL).

    Published date:
    11/26/2020
    Excerpt:
    …in pts with R/R FL gr1-3a, MZL…lenalidomide 20 mg/d, d1-21/28 + rituximab 375 mg/m2/wk c1 and then q8wk c3+ (R2) are given...ORR was 69% with 40% CR/CRu. Median DOR was 39.0 mo, and median PFS was 40.1 mo…
    DOI:
    10.1016/j.htct.2020.10.372
    Trial ID:
    MAGNIFY